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Concerns  about  the risk  of  inducing  immune  deviation-associated  “neonatal  tolerance”  as  described  in
mice  have  restricted  the  widespread  adoption  of  neonatal  vaccination.  The  aim  of  this  study  was  to
demonstrate  the  immunological  feasibility  of  neonatal  pneumococcal  conjugate  vaccination  (PCV)  which
could  potentially  protect  high-risk  infants  in  resource  poor  countries  against  severe  pneumococcal  dis-
ease  and  mortality  in  the  early  critical  period  of  life.  Papua  New  Guinean  infants  were  randomized  to be
vaccinated  with  the  7-valent  PCV  (7vPCV)  at birth,  1  and  2 months  (neonatal  group,  n  =  104)  or  at  1, 2  and
3  months  of  age  (infant  group,  n  = 105),  or to  not  receive  7vPCV  at all  (control  group,  n  = 109).  Analysis  of
vaccine  responses  at 3 and  9  months  of  age  demonstrated  persistently  higher  type-1  (IFN-)  and  type-2
(IL-5  and  IL-13)  T-cell  responses  to the  protein  carrier  CRM197 and  IgG  antibody  titres  to  7vPCV  serotypes
in  children  vaccinated  with  7vPCV  according  to either  schedule  as compared  to unvaccinated  children.
In  a comprehensive  immuno-phenotypic  analysis  at  9  months  of  age,  no differences  in  the  quantity  or
quality  of  vaccine-speciﬁc  T cell  memory  responses  were  found  between  neonatal  vaccinations  versus
children  given  their  ﬁrst  PCV  dose  at one  month.  Hospitalization  rates  in  the  ﬁrst  month  of life  did  not
differ  between  children  vaccinated  with  PCV  at birth  or  not.  These  ﬁndings  demonstrate  that  neona-
tal  7vPCV  vaccination  is safe and  not  associated  with  immunological  tolerance.  Neonatal  immunisation
schedules  should  therefore  be  considered  in  high-risk  areas  where  this  may  result  in  improved  vaccine
coverage  and  the  earliest  possible  protection  against  pneumococcal  disease  and  death.. Introduction
Findings by Medawar and colleagues [1] in the 1950s that infant
ammals fail to reject allografts expressing antigens they have
een exposed to in foetal and neonatal life gave rise to the con-
ept of neonatal tolerance. A series of landmark studies in 1996
2–4] collectively demonstrated that rather than deletional toler-
nce, this phenomenon represented ‘immune deviation’ involving
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selective activation of T helper 2 (Th2) immunity by function-
ally immature neonatal antigen presenting cells (APC), resulting
in attenuation of the class of immunity (Th1) that is central to graft
rejection. The process may  represent the transient carry-over of a
functional phenotype which dominates the innate immune system
during foetal development, the purpose of which is to attenuate the
production at the foetal-maternal interface of Th1 cytokines which
are highly toxic towards the placenta [5,6].
These ﬁndings have raised legitimate concerns regarding the
potential risks of neonatal vaccination against pathogens, namely
that vaccination during neonatal life when antigen presenting
cells retain their foetal-like Th2-selectivity, may  inadvertently
compromise the capacity to develop effective and persistent Th1-
polarised immunity. This concern has been supported by data from
neonatal vaccination studies in mice [7,8] and studies in humans
Open access under CC BY license.demonstrating a general type-2 polarisation of T-cell memory to
certain vaccines other than Bacillus Calmette-Guérin (BCG) follow-
ing infant priming [9–14]. As a result this issue continues to cast a
shadow of doubt over the possibility of immunizing neonates. This
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s of a particular concern in neonates in resource poor countries as
hey especially are subjected to a high mortality rate from vaccine
reventable diseases. Moreover, neonatal immunisation is likely
o improve overall vaccine coverage as mothers are more likely to
ome into contact with health services around the time of delivery
15,16]. Hence, neonatal immunisation might be more favourable
han infant immunisation if proven to be safe and equally immuno-
enic.
In 2008 alone, an estimated 0.9 million newborns died of sepsis
r pneumonia [17]: a number that could be reduced by neonatal
accination strategies. To study the immunological feasibility of
neumococcal vaccination in human newborns, we directly com-
ared immune responses to PCV in newborns and older infants
n Papua New Guinea (PNG): continuing our previous published
ork on early vaccine responses at 3 months of age [18], mem-
ry T-cell responses to the vaccine protein carrier CRM197 were
mmuno-phenotyped and compared between the three groups at
 months of age by means of in vitro cytokine response assays for
ll study participants, complemented with microarray studies com-
aring genome-wide T-cell related gene expression in a randomly
hosen subgroup of children in the neonatal compared to the infant
roup (n = 25 per group). In addition, aiming to address the func-
ionality of the memory T-cell responses, PCV-serotype speciﬁc IgG
ntibody titres were determined and studied in relation to in vitro
accine protein carrier speciﬁc cytokine responses.
. Materials and methods
.1.  Study design and participants
The  study area and population recruitment in PNG have been
escribed elsewhere [18]. Brieﬂy, pregnant women were recruited
t the antenatal clinic of Goroka Hospital and in villages located
ithin an hour’s drive of Goroka town. Inclusion criteria were the
ntention to remain in the study area for at least 2 years, a birth
eight of at least 2000 g, no acute neonatal infection and no severe
ongenital abnormality.
Newborns  (n = 313) were randomised to receive 7vPCV
Prevnar®, Wyeth) within 3 days of birth, 1 and 2 months (neonatal
roup, n = 104), at 1, 2 and 3 months (infant group and correspond-
ng with the PNG national expanded program on immunisation age,
 = 105), or to receive no 7vPCV (control group, n = 109). In accor-
ance with the PNG national expanded program on immunisation,
ll study children received BCG (birth); oral polio vaccine (neonatal,
, 2 and 3 months), Hepatitis B (neonatal, 1 and 3 months), a com-
ined Haemophilus inﬂuenzae type b, diphtheria, tetanus, whole cell
ertussis vaccine (TETRActHib) (1, 2 and 3 months), and measles
accine (6 and 9 months).
A  data safety monitoring board (DSMB) was  established and
as immediately advised of any serious adverse events and of all
dverse events 3-monthly.
This  trial is registered at ClinicalTrials.gov under regis-
ration number NCT00219401 (http://clinicaltrials.gov/ct2/show/
CT00219401).
.2.  Ethical considerations
Assent  was  sought from women and their partners at the time
f recruitment. Written informed consent was obtained after deliv-
ry and before enrolment of the newborn child. Ethical approval
as obtained from the PNG Medical Research Advisory Commit-
ee and the Princess Margaret Hospital Ethics Committee in Perth,
ustralia.cine 29 (2011) 5414– 5420 5415
2.3. Serum collection and isolation of peripheral mononuclear
cells (PBMC)
At  3 and 9 months of age, venous blood samples (1–2.5 ml)  were
collected into empty 2-ml tubes (serum) and 10-ml sterile tubes
containing 100 IU preservative-free heparin (PBMC). Samples were
centrifuged within 2 h to separate serum/plasma and aliquots were
stored at −20 ◦C. PBMC were isolated from the remaining heparin
tube cell pellet by centrifugation over a Ficoll-Hypaque gradient
(Lymphoprep, Alexis-Shield, Oslo, Norway) and cryo-preserved in
50% heat-inactivated (HI) foetal calf serum (FCS) and 7.5% DMSO.
Cells were kept under liquid nitrogen vapour phase conditions dur-
ing storage at IMR, transport to and storage at the Telethon Institute
of Child Health Research (ICHR).
2.4. In vitro PBMC cultures
PBMC  were cultured in duplicate in 96-wells plates
(1 × 106 cells/ml) in medium (RPMI/5% HI-inactivated human
AB serum) (Pharmacia Australia Pty. Ltd., Sydney, Australia) or
stimulated with CRM197 (kindly provided by former Wyeth Phar-
maceuticals, USA) (2.5 g/ml), Tetanus Toxoid (TT; CSL, Victoria,
Australia) (0.5 lf/ml), measles lysate (kindly provided by Steven
Wesselingh and Diane Webster, Macfarlane Burnet Institute for
Medical Research, Melbourne, Australia) (4 × 105 particles/ml) and
phytohemagglutinin (PHA; Remel Europe Ltd., Kent, UK) (positive
control, 1 g/ml). Supernatants were collected after 96 h (48 h
for PHA). Due to low blood volumes, sufﬁcient PBMC for in vitro
CRM197 experiments (including negative and positive controls)
were available for 198 children at 3 months (neonatal 68; infant
68; control 62) [18] and 222 children at 9 months (neonatal 74;
infant 76; control 72); 132 children (neonatal 48; infant 46; control
38) had in vitro CRM197 data available for both time points. For 9
months samples, in vitro stimulations with TT and measles lysate
could be performed for 99 (neonatal, n = 40; infant, n = 28; control,
n = 31) and 113 children (neonatal, n = 43; infant, n = 33; control,
n = 37), respectively.
2.5. Cytokine protein detection
Cytokine  levels were measured using an in-house multiplex
assay. Brieﬂy, microspheres (MagPlex, Luminex®, USA) coupled to
azide-free primary antibodies against IL-5, IL-6, IL-9, IL-10, IL-12,
IL-13 and TNF (Becton Dickinson, USA) and IFN- and IL-1 (eBio-
science, USA) in PBS-BN (PBS + 1% BSA + 0.05% Sodium Azide, pH 7.4)
(1 × 106 beads/ml) were plated onto 96-well plates (Costar®, USA)
(50 l/well), followed by the addition of cytokine standards, qual-
ity controls, or samples. Standards were diluted in culture media
and assay buffer (PBS + 1%BSA), and quality controls and samples
in assay buffer. A magnetic bead separator was used to wash the
plates. After addition and incubation with biotinylated-secondary
antibodies, plates were incubated with streptavidin-PE (Becton
Dickinson, USA) (1:1000 in assay buffer), washed and assay buffer
was added before reading on a Bio-Plex Suspension Array System
(BIO-RAD, USA). Samples with concentrations below the detection
limit were given the value corresponding to half the lowest con-
centration that could be detected in this set of samples.
2.6. Microarray studies
In  a time course experiment a 72 h in vitro culture period
was found to best capture the expression of both early and late
CRM197-induced memory T-cell genes (target genes: IL-2, IL-4, IL-
5, IL-9, IL-13, IL-17, IFN, CXCL10, GZMB, LIF and Foxp3; data
not shown). Total RNA was extracted from non-stimulated and
CRM197-stimulated PBMC (25 neonatal; 25 infant) using TRIzol
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Invitrogen) followed by RNeasy (Qiagen). For each microarray
xperiment, 150 ng of pooled RNA of 5 subjects belonging to the
ame study arm was labelled and hybridized to Human Gene
.0 ST microarrays (Affymetrix), employing standardized pro-
ocols and reagents from Affymetrix (total of 20 microarrays).
icroarray data were pre-processed in Expression Console soft-
are (Affymetrix) using the probe logarithmic intensity error
lgorithm, then imported into the R environment (version 2.9.1;
ww.r-project.org) for further analysis [19]. Signiﬁcance analy-
is of microarrays (SAM) [20] was employed to identify genes
hat were signiﬁcantly modulated in response to CRM197 stim-
lation and compare CRM197-speciﬁc gene expression proﬁles
etween the two groups: to account for multiple testing, SAM
ses an internal procedure to estimate the false discovery rate
FDR) [21]. DAVID Bioinformatics Resources 6.7 was  used to iden-
ify functional clusters amongst induced genes [22]. The microarray
ata are available in the Gene Expression Omnibus repository
www.ncbi.nlm.nih.gov/projects/geo/) under the accession num-
er GSE25263.
.7.  Quantitative real time PCR
Reverse transcription was performed using the Qantitect kit
Qiagen, USA) according to the manufacturer’s protocol with
ligo-dT (Promega, USA) and Superasin (GeneWorks, Australia).
ntron-spanning primers for IL-2, IL-2Ra, IL-4, IL-5, IL-9, IL-13, IL-
7F, IL-17RB, IFN, CXCL10, GZMB, LIF and Foxp3 were obtained
rom http://pga.mgh.harvard.edu/primerbank and designed in-
ouse using Primer Express Software (Applied Biosystems, USA).
everse-transcribed RNA samples were diluted 1/5 and quantitated
y real-time PCR using QuantiTect SYBR Green Master Mix  (Qia-
en) on the ABI PRISM 7900HT (Applied Biosystems). Copy numbers
ere determined by 10-fold serial dilutions of plasmid standards
nd normalized to the reference gene eukaryotic translation elon-
ation factor 1 alpha 1 (EEF1A1).
.8.  Pneumococcal capsular polysaccharide ELISA
Serum IgG antibodies to PCV serotypes (4, 6B, 9V, 14, 18C, 19F
nd 23F) were measured using a WHO  standardised ELISA [23].
rieﬂy, microtitre plates (Greiner, Germany) were coated with cap-
ular polysaccharide antigens for 5 h at 37 ◦C. Serum samples were
dded after overnight absorption with 10 g/ml cell wall polysac-
haride and 5 g/ml serotype 22F. The WHO  reference serum 89SF
FDA, Bethesda, MD)  was pre-absorbed with 10 g/ml cell wall
olysaccharide. Goat anti-human IgG conjugate (Biosource, CA,
SA) and pnPP substrate (Sigma, USA) were used for detection. Each
late contained a high and low in-house quality control serum to
ssess intra- and inter-assay variations.
.9. Statistical analysis
Statistical  analysis of data other than the microarray studies
ere performed using SPSS 15.0. To compare categorical variables,
he Pearson chi-square and Cramer’s V were calculated for 2 ×2 and
 × 3 tables respectively. Mann–Whitney tests or Kruskal–Wallis
ests were used to compare continuous data in two or three groups,
espectively. Cytokine responses were log10-transformed and data
resented as geometric means (GM) ± the standard error of the
eometric means (SEGM). Spearman rank correlation analysis was
erformed to study correlations between 7vPCV serotype-speciﬁc
gG antibody titres and CRM197-speciﬁc cytokine responses. For
ll analysis, test outcomes were considered to be signiﬁcant if the
-value was smaller or equal to 0.05.ccine 29 (2011) 5414– 5420
3.  Results
3.1. Study numbers
Population characteristics for the children at the time of enrol-
ment have been described elsewhere [18]. Of the 313 children
enrolled at birth, 255 were eligible for follow-up and data anal-
ysis at 9 months of age (neonatal 81; infant 91; control 83): of the
58 children lost to the study at 9 months, parental consent was
withdrawn for 32 children (neonatal, n = 14; infant, n = 7; control,
n = 11); 10 children were lost to follow-up due to migration out
of the study area (neonatal, n = 3; infant, n = 1; control, n = 6); 15
children were excluded from analysis due to protocol violations
(neonatal, n = 4; infant, n = 3; control, n = 8); and one child died
(infant group). Sufﬁcient PBMC for in vitro CRM197 stimulations
were available for 222 children (neonatal 74; infant 76; control 72)
at 9 months of age; for 132 children cell culture data at both 3 and
9 months of age were available (neonatal 48; infant 46; control 38).
3.2. Neonatal and infant PCV vaccination induces persistent
memory responses
The  capacity of either vaccination schedule to induce persistent
immune memory was assessed by determining vaccine responses
at 3 months of age when children in the infant group were still
to receive a 3rd dose of PCV, and at 9 months of age, long after
completion of the different immunisation schedules.
In Fig. 1A, in vitro type-1 (IFN-) and type-2 (IL-5 and IL-13)
T-cell memory cytokine responses to the vaccine carrier protein
CRM197 are shown for 132 study children with data available at both
3 and 9 months of age: type-1 and type-2 CRM197 responses were
found to be higher in PCV-vaccinated children compared to unvac-
cinated children at both 3 and 9 months of age, which conﬁrms
that both 7vPCV immunisation schedules induced persistent T-cell
memory responses. The higher Th2-recall response at 3 months of
age in the neonatal compared to the infant group (IL-5, p = 0.044;
IL-13, p = 0.051) [18], was  no longer apparent at 9 months of age.
There was no evidence that co-immunisation with BCG at birth
inﬂuenced CRM197-induced T-cell responses at 3 months [18] or 9
months of age (data not presented).
Accordingly, at both 3 and 9 months of age serum pneumococ-
cal serotype-speciﬁc IgG antibody titres were found to be higher
and exceed the assumed clinically protective level of 0.35 g/ml
for most PCV serotypes in children who  had received 7vPCV com-
pared to those who  had not, conﬁrming the induction of protective
immune responses in both immunisation schedules (Fig. 1B).
3.3. Neonatal and infant vaccination induce identical recall
responses
We  next performed a comprehensive immuno-phenotypic anal-
ysis of the CRM197-speciﬁc T-cell memory response at 9 months
to conﬁrm that recall responses were similar under neonatal and
infant immunisation schedules.
Comparison  of in vitro T-cell memory cytokine responses
to the vaccine carrier protein CRM197 demonstrated that recall
responses were characterized by a mixed pattern of type-1/type-2
responses and were comparable in the neonatal and infant groups
(Fig. 2A), with only a minority of children displaying exclusively
Th2 responses (Fig. 2B).
We next progressed to genome-wide expression proﬁling of T-
cell memory responses in a subpopulation of randomly selected
children (n = 25 per group). In the neonatal group in vitro CRM197
stimulation was found to result in a signiﬁcant differential expres-
sion of 105 genes and in the infant group of 140 genes (78 mutual)
(Supplementary Fig. 1A and Table 1). The expression levels of these
A.H.J. van den Biggelaar et al. / Vaccine 29 (2011) 5414– 5420 5417
Fig. 1. CRM197-speciﬁc type-1 and type-2 recall responses at 3 and 9 months of age. (A) Geometric means and standard errors of geometric means of CRM197-induced IFN-
(T helper 1), IL-5 and IL-13 (T helper 2) protein responses at 3 and 9 months (©, neonatal n = 48; , infant, n = 46; , control, n = 38). The letters indicate signiﬁcant differences
(p < 0.05) for each time point between (a) the neonatal vs. infant group, (b) the neonatal vs. control group and (c) the infant vs. control group, and within groups for 3 compared
to  9-month responses for the (d) infant and (e) control group (no statistical differences were found within the neonatal group). (B) Pneumococcal vaccine serotype-speciﬁc
I nd co
c
C
g
g
s
a
t
g
m
(
3
p
r
n
t
a
s
i
T
SgG antibody responses in the neonatal (white bar, n = 44), infant (grey bar, n = 40) a
orrelate of protection against invasive pneumococcal disease [35].
RM197 response genes did not differ between the two vaccination
roups (Supplementary Fig. 1B) and this is illustrated in Fig. 2C for
enes that are involved in T-helper cell differentiation or respon-
iveness. Since microarray data were based on pooled RNA samples
nd could be inﬂuenced by individual outliers, we  performed quan-
itative RT-PCR analysis for a deﬁned set of memory T-cell related
enes in individual samples. In line with the microarray data,
RNA expression levels were similar in the two  vaccination groups
Fig. 2D).
.4.  Neonatal immunisation induces functional type-1 and
ermissive  type-2 responses
To  address the functionality of the vaccine-induced type-1
esponse and the potential negative effect of type-2 responses to
eonatal vaccination, we studied in the neonatal group correla-
ions between CRM197-speciﬁc IFN-, IL-5 and IL-13 responses at
ge 3 months (1 month after the 3rd dose of PCV) and PCV serotype-
peciﬁc IgG antibody titres at age 3 and 9 months. As demonstrated
n Table 1, CRM197-IFN- responses at age 3 months correlated sig-
able 1
pearman correlations for 3-month CRM197 responses and 3 and 9 month 7vPCV serotyp
3-Month IgG 
CRM197 response at 3 months 
IFN- IL-5 IL-13 
rho p-Value rho p-Value rho p-Valu
Serotype 4 0.375 0.004 0.459 <0.001 0.379 0.004
6B  0.157 0.227 0.367 0.004 0.231 0.073
9V  0.272 0.032 0.206 0.108 0.147 0.253
14 0.107  0.413 0.310 0.015 0.202 0.119
18C 0.352  0.005 0.245 0.057 0.189 0.144
19F  0.118 0.362 0.300 0.018 0.162 0.208
23F 0.420  0.001 0.491 <0.001 0.502 <0.001ntrol group (black bar, n = 32). A level of 0.35 g/ml or more is considered a clinical
niﬁcantly  with antibody titres at 9 months; this conﬁrms the ability
of neonatal immunisation to induce functional type-1 immunity.
Furthermore, the positive associations between the Th2 response
and circulating antibody titres at age 3 months suggest that Th2
responses do not negatively interfere with the induction of immu-
nity, but rather facilitate responses, possibly by driving initial B-cell
switching and proliferation.
3.5.  Immunological safety of neonatal vaccination
One measure of demonstrating the safety of neonatal vaccina-
tion is excluding the possibility of any interference with cellular
immune responses to expanded program of immunisation (EPI)
vaccines or with normal maturation of the immune system. We
have previously demonstrated that at 3 months of age type-1 and 2
cytokine responses to the concomitant vaccine antigens PPD (BCG),
HbsAg (HepB) and TT (DTwP/Hib), and polyclonal T cell responses
to PHA were similar in the 3 study groups [18]. Repeating this mea-
sure at 9 months of age for responses to TT and PHA as well as the
later administered measles vaccine (1st dose at 6 months of age),
e-speciﬁc IgG antibody titres in the neonatal group.
9-Month IgG
CRM197 response at 3 months
IFN- IL-5 IL-13
e rho p-Value rho p-Value rho p-Value
 0.524 <0.001 0.183 0.181 0.175 0.202
 0.474 <0.001 0.072 0.614 0.161 0.259
 0.307 0.024 0.233 0.091 0.136 0.326
 0.259 0.064 0.002 0.988 0.019 0.891
 0.294 0.032 0.160 0.253 0.081 0.565
 −0.008 0.956 0.012 0.934 −0.042 0.765
 0.271 0.050 0.154 0.272 0.138 0.326
5418 A.H.J. van den Biggelaar et al. / Vaccine 29 (2011) 5414– 5420
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Fig. 2. Immunophenotypic analysis of recall T cell responses at 9 months following neonatal or infant immunisation. (A) Background-adjusted protein cytokine responses
to CRM197 in the neonatal (white bar; n = 65) and infant groups (grey bar; n = 62) at 9 months. (B) Proportion of children responding with an exclusive Th1 (IFN-) (black),
mixed Th1/Th2 (IFN-, and IL-5 and/or IL-13) (dark grey), exclusive Th2 (IL-5 and/or IL-13) (light grey), or no protein cytokine response to CRM197 (positive response ≥ 4
times the background) (white). (C) Microarray-assessed log2-fold differential gene expression (mean and standard error of the mean) in CRM197-stimulated cells compared
to that in un-stimulated cells in the neonatal (white bar, n = 5 × 5 pooled PBMC) and infant groups (grey bar, n = 5 × 5 pooled PBMC). (D) Quantitative RT-PCR based relative
mRNA expression in CRM197-stimulated compared to that in un-stimulated PBMC in the neonatal (©, n = 20) and infant group ( , n = 20), normalized against the constantly
expressed gene eukaryotic translation elongation factor 1 a 1 (EEF1A1). CSF2, colony stimulating factor 2; CXCL9, Chemokine (C-X-C motif) ligand 9; GZMB, Granzyme B;
IFNG,  interferon-; Interleukin, IL; LIF, Leukemia inhibitory factor; LTA, lymphotoxin A.
Fig. 3. Bystander T cell cytokine responses. Background adjusted in vitro cytokine responses to tetanus toxoid (neonatal, n = 40; infant, n = 28; control, n = 31), measles lysate
(neonatal, n = 43; infant, n = 33; control, n = 37) or phytohemagglutinin (PHA) (neonatal, n = 74; infant, n = 74; control, n = 72) at 9 months of age. (a) indicates signiﬁcant
difference in the neonatal compared to infant group.
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ellular immune responses were again found to be similar in the
hree groups (except for higher PHA-TNF responses in the infant
han in the neonatal group, p = 0.004) (Fig. 3).
Hospitalization in the ﬁrst month of life children did not dif-
er between children in the neonatal vaccination group (1.3/1000
erson days) compared to those who had not received a neona-
al dose (3.0/1000 person days) (p = 0.18), indicating that neonatal
accination did not impose an early health risk.
. Discussion
In this study we have shown in human newborns at high risk
f pneumococcal disease and death that both neonatal and infant
CV immunisation schedules successfully prime and induce per-
isting protective immune responses in these high-risk infants; that
eonatal immunisation with PCV induces a similar type-1/type-2
emory response as vaccination starting at the current PNG EPI age
f 1 month (which is a bit earlier than most schedules starting at
 weeks of age in developing countries); and that vaccine-induced
h2 responses do not negatively interfere with the induction of
mmunity.
Our results are in disagreement with mouse studies show-
ng that vaccination in early life induces skewed Th2 responses,
ith little development of sterilizing Th1 immunity. Although the
rimary response in neonatal mice appears to compromise both
h1 and Th2 cells [24], Th1 cells appear to undergo apoptosis in
esponse to a secondary challenge while Th2 cells remain respon-
ive [25,26]. To date, only a few human studies have reported on
he effect of neonatal vaccination on T-cell development. Whereas
acillus Calmette-Guérin induces adult-like Th1 responses when
dministered at birth [27–29], the capacity of other vaccines
o induce type-1 responses is lower in neonates than in adults
nless responses are enhanced by co-administered BCG [9,12–14];
owever, the clear skewing towards Th2-type responses and elim-
nation of Th1 responses that is observed in mice [30] is not readily
pparent in human newborns. By comparing recall responses in
nfants that completed a 3-dose immunisation schedule starting
ither shortly after birth or after the neonatal period at the age
f 1 month, we have been able to demonstrate that, in line with
ndings for BCG, neonatal immunisation with other vaccines such
s this pneumococcal conjugate vaccine is safe and not associated
ith immune deviation.
Alongside  the induction of competent Th1 responses, neona-
al and infant PCV vaccination elicited comparable Th2 responses
hat, as illustrated by initial positive associations with vaccine anti-
ody titres, were facilitating and not attenuating protective vaccine
erotype-speciﬁc responses. Although DT- and CRM197-containing
onjugate vaccines such as the PCV used in this study have been
ssociated with vaccine interference [31], no evidence for this was
ound in our study. We  therefore believe that the neonatal Th2
ilieu does not pose more risks than vaccination schedules start-
ng later in infancy and that the induction of Th2 responses is not
n impediment to neonatal vaccination.
We found that serum IgG antibody titres varied according to
neumococcal serotype; this is a well-recognized phenomenon to
oth unconjugated and conjugated pneumococcal vaccines. Anti-
ody titres might also be affected by carriage of pneumococcal
erotypes commonly circulating in the community such as serotype
9F for which non-vaccinated children also showed high antibody
itres. Moreover, 19F has been reported to be the least efﬁcacious
omponent of PCV [32], which may  explain that in contrast to our
ndings for the other six PCV serotypes CRM197-IFN- responses
t age 3 months did not correlate signiﬁcantly with IgG antibody
esponses to 19F at 9 months.cine 29 (2011) 5414– 5420 5419
A  limitation of our neonatal vaccination trial was the small
blood volume that could be obtained from young infants; this
restricted the breadth and depth of immunological experiments
that could be performed. Nevertheless, we have been able to per-
form and present a comprehensive immuno-phenotypic analysis of
vaccine responses within the ﬁrst nine months of infancy, includ-
ing genome-wide microarray and RT-PCR experiments in addition
to in vitro cell cultures and serum antibody responses measured
at different time points. Since the aim of this trial was to demon-
strate the safety and immunogenicity of neonatal PCV vaccination,
the study was not powered to demonstrate any clinical beneﬁt
of neonatal PCV vaccination. However, our data strongly support
larger randomized controlled trials to assess efﬁcacy.
In  conclusion, in humans neonatal vaccination with PCV induces
similar T helper memory development as vaccination later in
infancy: this ﬁnding challenges the paradigm described in mice
that neonatal immunisation induces immune deviation-associated
“neonatal tolerance”. Furthermore, our study highlights the impor-
tance of understanding the role of T helper cells in vaccine
responses in paediatric populations, all the more so considering
the expanding use of polysaccharide conjugate vaccines [33] and
increasing interest in using vaccine adjuvants to enhance cellular
immune responsiveness [34].
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